GTM:NASDAQZoomInfo Technologies Inc. Analysis
Data as of 2026-04-07 - not real-time
$5.94
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
ZoomInfo (GTM) is trading at $5.94, well below its DCF‑derived fair value of roughly $13.9, implying more than 50% upside. The 20‑day SMA ($5.96) sits just above the current price while the 50‑day SMA ($6.56) remains higher, confirming a short‑term bearish bias. RSI at 44 signals a neutral to slightly oversold condition, and the MACD histogram is positive, hinting at a modest bullish momentum emerging. Volume is on a decreasing trend, and the stock is hovering just above the identified support at $5.57, with resistance near $6.58. Volatility is elevated at nearly 48% over the past 30 days and beta exceeds 1.6, underscoring heightened price swings.
Fundamentally, revenue grew only 3.2% YoY and profit margins sit at 10%, but the forward PE of 5.1 and a forward EPS of $1.16 suggest earnings acceleration. The balance sheet is leveraged, with a debt‑to‑equity ratio over 100% and total debt surpassing cash, raising solvency concerns. Recent earnings beat was tempered by cautious 2026 guidance, a $1 billion share‑repurchase program, and ongoing securities litigation that adds regulatory risk. Despite these headwinds, the RPD Fund has added to its position and insider sales have been flagged, while the stock has found a 52‑week low, creating a potential buying opportunity for value‑oriented investors.
Fundamentally, revenue grew only 3.2% YoY and profit margins sit at 10%, but the forward PE of 5.1 and a forward EPS of $1.16 suggest earnings acceleration. The balance sheet is leveraged, with a debt‑to‑equity ratio over 100% and total debt surpassing cash, raising solvency concerns. Recent earnings beat was tempered by cautious 2026 guidance, a $1 billion share‑repurchase program, and ongoing securities litigation that adds regulatory risk. Despite these headwinds, the RPD Fund has added to its position and insider sales have been flagged, while the stock has found a 52‑week low, creating a potential buying opportunity for value‑oriented investors.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price near support with upside potential
- Positive MACD histogram indicating early momentum
- Share‑repurchase program signaling management confidence
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Cautious earnings guidance limiting near‑term growth
- High leverage increasing financial risk
- Ongoing legal investigations adding uncertainty
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value suggests substantial long‑run upside
- Forward PE of 5.1 reflects strong earnings outlook
- Market positioning in a high‑growth B2B SaaS niche
Key Metrics & Analysis
Financial Health
Revenue Growth3.20%
Profit Margin9.94%
P/E Ratio15.6
ROE7.76%
ROA2.58%
Debt/Equity104.01
P/B Ratio1.2
Op. Cash Flow$465.4M
Free Cash Flow$365.8M
Industry P/E32.5
Technical Analysis
TrendBearish
RSI44.2
Support$5.57
Resistance$6.57
MA 20$5.96
MA 50$6.56
MA 200$9.45
MACDBullish
VolumeDecreasing
Fear & Greed Index76.82
Valuation
Fair Value$13.93
Target Price$9.29
Upside/Downside56.39%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.66
Volatility48.51%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.